Oragenics (NYSE American: $OGEN) Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines TAMPA, Fla. - July 27, 2021 (Investorideas.com Newswire) Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Medical Tech Stock News: Neovasc (NASDAQ: NVCN) to Report Second Quarter 2021 Financial Results on August 10, 2021 Vancouver, British Columbia - July 27, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.

Coverage Initiated on Company with a 'Genuine Physiological Heart Replacement Therapy' July 22, 2021 (Investorideas.com Newswire) The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report.

Biopharma Partners with NIH to Advance Women's Hormone-Free Contraceptive July 22, 2021 (Investorideas.com Newswire) A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience.

Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant July 21, 2021 (Investorideas.com Newswire) Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets.

Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data July 20, 2021 (Investorideas.com Newswire) Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial.

Zynex Shares Rise as Firm Notches Significant Q2 Order Growth and Raises EBITDA Outlook July 19, 2021 (Investorideas.com Newswire) Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million.

Pharma Stock News: NRx Pharmaceuticals (Nasdaq: $NRXP) Presents Evidence ZYESAMI (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19 RADNOR, Pa. - July 19, 2021 (Investorideas.com Newswire) NRx Pharmaceuticals (Nasdaq: NRXP), will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10:10 EST

FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design July 15, 2021 (Investorideas.com Newswire) The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report.

Merger of Two Biopharmas 'Brings a New Dawn' July 15, 2021 (Investorideas.com Newswire) The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021

Resources for Physicians and Medical Practices - December 31, 2020

Lockdown Part 2: The South African Economy and the Rand - December 15, 2020

How to Get Into Canada during COVID - November 30, 2020

The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020

Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020

Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020

The Rise Of The At-Home Testing Market - January 16, 2020

Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019

5 Key Tips For Renting a Boardroom - August 14, 2018

How to Go About Choosing a Medical Malpractice Lawyer - February 13, 2018

Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers Validates Cepharanthine's potential in treating various cancers with unsatisfactory treatment optionsPositions Cepharanthine's 'pipeline in a pill' strategy focusing on esophageal, colorectal, liver and skin cancersAdvance to FDA IND-enabling studies to support human clinical studiesToronto, Ontario--(Newsfile Corp. - July 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved...

Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry at the University of Alberta. Dr. Greenshaw is a Fellow of the Royal Society of Arts; a Fellow of the...

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept - "Never Before Accomplished" A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer's Disease/PTSD/CTE Jackson Center, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Halberd Corporation (OTC Pink: HALB) establishes "proof of concept" taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating E. Coli bacteria through the use of its patent-pending laser emissive energy exposure technique. Recently, at Youngstown State University (YSU) and Arizona State University (ASU), the bacteria was mixed with a metallic...

Relay's Cybeats Joins the Internet of Things Security Foundation Toronto, Ontario--(Newsfile Corp. - July 28, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), is pleased to announce that its integrated cybersecurity platform Cybeats has joined the Internet of Things Security Foundation ("IoTSF" or the "Foundation") to support and champion the formulation of best practices for consumer and regulatory adoption of cybersecurity. The IoTSF is a global non-profit organization with the mission to help secure the Internet...

Universal PropTech Announces Partnership Agreement with Termobuild for Carbon Neutral Building Solutions Toronto, Ontario--(Newsfile Corp. - July 27, 2021) - Universal PropTech Inc. (TSXV: UPI) (OTCQB: UPIPF) (FSE: 8LH) ("UPI" or the "Company") is pleased to announce that the Company has signed a Partnership Agreement ("Agreement") with Laken & Associates Inc. o/a Termobuild ("Termobuild") to incorporate the use of Termobuild value engineering and hollow core concrete technology to develop carbon neutral building solutions for real estate developers and builders in Canada."As Universal PropTech embarks on developing energy...

Subscribe to Biotech News